Evidence map›Paper›PMID 35097226›Full record

ArticleClinical and translational radiation oncology2022

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.

Alexander F Bagley, Ethan B Ludmir, Anirban Maitra, Bruce D Minsky, Grace Li Smith, Prajnan Das, Albert C Koong, Emma B Holliday, Cullen M Taniguchi, Matthew H G Katz and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Golden era of radiosensitizers.Frontiers in veterinary science · 2024
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alexander F BagleyThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan B LudmirThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anirban MaitraThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bruce D MinskyThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Grace Li SmithThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prajnan DasThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Albert C KoongThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma B HollidayThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cullen M TaniguchiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew H G KatzThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eric P TammThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert A WolffThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J OvermanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shivani PatelThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael P KimThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ching-Wei D TzengThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naruhiko IkomaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manoop S BhutaniThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eugene J KoayThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic CancerR01CA227517 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOONG, ALBERT · 2019 to 2023
$2.3M
NCI NIH HHS R01 CA227517
6 · The paper itself

Abstract

background and purposePancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in the world. For patients with PDAC who are not eligible for surgery, radiation therapy improves local disease control, yet safely delivering therapeutic doses of radiation remains challenging due to off-target toxicities in surrounding normal tissues. NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, has recently shown clinical activity in soft tissue sarcoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, and advanced solid malignancies with lung or liver metastases. Here we report the first patient with pancreatic cancer treated with NBTXR3. MATERIALS AND

methodsA 66-year-old male with unresectable locally advanced PDAC was enrolled on our clinical trial to receive NBTXR3 activated by radiation therapy. Local endoscopic delivery of NBTXR3 was followed by intensity modulated radiation therapy (IMRT). Follow-up assessment consisted of physical examination, laboratory studies including CA19-9, and CT of the chest, abdomen, and pelvis.

resultsThe patient received NBTXR3 by local endoscopic delivery without any acute adverse events. Radiation treatment consisted of 45 Gy in 15 daily fractions using IMRT. The patient began radiation twelve days after NBTXR3 injection. Daily CT-on-rails imaging demonstrated retention of NBTXR3 within the tumor for the duration of treatment. At initial follow-up evaluation, the lesion remained radiographically stable and the patient did not demonstrate treatment-related toxicity.

conclusionThis report demonstrates initial feasibility of local endoscopic delivery of NBTXR3 activated by radiation therapy for patients with pancreatic cancer who are not eligible for surgery.

Identifiers

PMID35097226
PMCPMC8783106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.